Breast Cancer Mortality Rates Down

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

WASHINGTON--The breast cancer death rate in American women has declined steadily in the 1990s, suggesting that improved breast cancer management from early detection to treatment is having a beneficial effect, the National Cancer Institute reports.

WASHINGTON--The breast cancer death rate in American women hasdeclined steadily in the 1990s, suggesting that improved breastcancer management from early detection to treatment is havinga beneficial effect, the National Cancer Institute reports.

From 1989 to 1993, age-adjusted mortality rates fell approximately6% in white women and rose about 1% in black women. This is animprovement over 1980 to 1989, when rates increased by 3% in whitewomen and 16% in black women.

The report attributed the decline in mortality only partly tomammography screening, stating that "further study is requiredto determine the relative contribution of early detection andimproved treatment."

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content